About this Journal Submit a Manuscript Table of Contents
ISRN Spectroscopy
Volume 2013 (2013), Article ID 572170, 6 pages
http://dx.doi.org/10.1155/2013/572170
Research Article

Development and Validation of RP-HPLC Method for Azilsartan Medoxomil Potassium Quantitation in Human Plasma by Solid Phase Extraction Procedure

Department of Chemistry, Saurashtra University, Rajkot 36005, India

Received 21 June 2013; Accepted 14 August 2013

Academic Editors: I. P. Gerothanassis, B. Liu, and S. Pandey

Copyright © 2013 Paras P. Vekariya and Hitendra S. Joshi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. European Medicines Agency, “Edarbi (Azilsartan Medoxomil Potassium),” Assessment Report Procedure no. EMEA/H/C/002293, 2011.
  2. Press announcement by The U.S. Food and Drug Administration, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm244722.htm.
  3. M. Gasparo, K. J. Catt, T. Inagami, J. W. Wright, and T. Unger, “International union of pharmacology. XXIII. The angiotensin II receptors,” Pharmacological Reviews, vol. 52, no. 3, pp. 415–472, 2000. View at Scopus
  4. M. Ojima, H. Igata, M. Tanaka et al., “In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies,” Journal of Pharmacology and Experimental Therapeutics, vol. 336, no. 3, pp. 801–808, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. G. L. Bakris, D. Sica, M. Weber et al., “The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure,” Journal of Clinical Hypertension, vol. 13, no. 2, pp. 81–88, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. W. B. White, M. A. Weber, D. Sica et al., “Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension,” Hypertension, vol. 57, no. 3, pp. 413–420, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Madhubabu and K. Bikshalbabu, “Reverse phase—Hplc method development and validation of azilsartan medoxomil and chlortalidone in pharmaceutical dosage form,” Journal of Atoms and Molecules, vol. 2, no. 1, pp. 117–126, 2012.
  8. “Guidance for industry: bio analytical method validation,” US Department of Health and Human Services, Food and Drug Administration, CDER, Rockville, Md, USA, May 2001, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.